• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anti-Vascular Endothelial Growth Factor/Programmed Cell Death Protein 1 Bispecific Antibodies: Using Nunchucks to Fight an Old Adversary.

作者信息

Dammeijer Floris, Dumoulin Daphne W, Aerts Joachim G J V

机构信息

Department of Pulmonary Medicine, Erasmus MC Cancer Institute, Erasmus University MC, Rotterdam, The Netherlands.

Department of Pulmonary Medicine, Erasmus MC Cancer Institute, Erasmus University MC, Rotterdam, The Netherlands.

出版信息

J Thorac Oncol. 2024 Mar;19(3):366-369. doi: 10.1016/j.jtho.2023.12.001.

DOI:10.1016/j.jtho.2023.12.001
PMID:38453322
Abstract
摘要

相似文献

1
Anti-Vascular Endothelial Growth Factor/Programmed Cell Death Protein 1 Bispecific Antibodies: Using Nunchucks to Fight an Old Adversary.抗血管内皮生长因子/程序性细胞死亡蛋白1双特异性抗体：用双节棍对抗老对手。
J Thorac Oncol. 2024 Mar;19(3):366-369. doi: 10.1016/j.jtho.2023.12.001.
2
Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in and Evaluation of Antitumor Activity In Vivo.优化表达和鉴定一种新型全人源双特异性单链二价抗体，针对血管内皮生长因子 165 和程序性死亡受体-1，并在体内评估其抗肿瘤活性。
Int J Mol Sci. 2018 Sep 25;19(10):2900. doi: 10.3390/ijms19102900.
3
Chemical generation of bispecific antibodies.化学法制备双特异性抗体。
Proc Natl Acad Sci U S A. 2010 Dec 28;107(52):22611-6. doi: 10.1073/pnas.1016478108. Epub 2010 Dec 13.
4
Full-length recombinant antibodies from : production, characterization, effector function (Fc) engineering, and clinical evaluation.全长重组抗体：生产、表征、效应功能（Fc）工程和临床评估。
MAbs. 2022 Jan-Dec;14(1):2111748. doi: 10.1080/19420862.2022.2111748.
5
A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities.一种新型双特异性抗体，靶向 PD-L1 和 VEGF，具有联合抗肿瘤活性。
Front Immunol. 2021 Dec 2;12:778978. doi: 10.3389/fimmu.2021.778978. eCollection 2021.
6
Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth.联合靶向 DLL3 的双特异性抗体与 PD-1 抑制可有效抑制小细胞肺癌生长。
J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2020-000785.
7
A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC.一项关于伊沃西单抗（一种程序性细胞死亡蛋白-1和血管内皮生长因子双特异性抗体）作为晚期或转移性初治非小细胞肺癌一线或二线治疗的1b期研究。
J Thorac Oncol. 2024 Mar;19(3):465-475. doi: 10.1016/j.jtho.2023.10.014. Epub 2023 Oct 23.
8
Preface.前言。
Adv Clin Chem. 2019;88:ix. doi: 10.1016/S0065-2423(18)30086-6.
9
Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition.双特异性 T 细胞结合抗体针对 MUC16 对卵巢癌的疗效在单药治疗和联合 PD-1 和 VEGF 抑制中得到证实。
Front Immunol. 2021 Apr 14;12:663379. doi: 10.3389/fimmu.2021.663379. eCollection 2021.
10
[Consideration on the Research and Development of Anti-tumor Bispecific Antibody Drugs].关于抗肿瘤双特异性抗体药物研发的思考
Zhongguo Fei Ai Za Zhi. 2022 Sep 20;25(9):684-688. doi: 10.3779/j.issn.1009-3419.2022.101.43.

引用本文的文献

1
Ivonescimab plus chemotherapy in advanced or metastatic non‑squamous non‑small cell lung cancer with EGFR variant in China: a cost-effectiveness analysis.在中国，伊沃西单抗联合化疗用于治疗具有表皮生长因子受体（EGFR）变异的晚期或转移性非鳞状非小细胞肺癌：一项成本效益分析。
Transl Lung Cancer Res. 2025 May 30;14(5):1622-1634. doi: 10.21037/tlcr-2024-1053. Epub 2025 May 22.